Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of PF-06700841 in active systemic lupus erythematosus
jRCT2080224867Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of brepocitinib in systemic lupus erythematosus (SLE) (4 arms), sponsored by Pfizer. Started Sep 2019; status: completed.
02
Drugs
brepocitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080224867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224867.